Cyclosporin A therapy in paraprotein-associated neuropathy.
A case of IgG paraprotein-associated demyelinating neuropathy complicated by respiratory failure, which was unresponsive to standard immunosuppressive drug therapy, is reported. Cyclosporin A therapy resulted in a marked clinical recovery with objective improvement in nerve conduction and vital capacity. The beneficial response suggests that cell-mediated immunity is an important pathogenetic mechanism, and that cyclosporin A may be useful in the treatment of other refractory cases of paraprotein-associated neuropathy.
Waterston
J A
JA
Department of Neurology, London Hospital, Whitechapel, United Kingdom.
Brown
M M
MM
Ingram
D A
DA
Swash
M
M
D000328:Adult; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use*; D003711:Demyelinating Diseases / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D006801:Humans; D007146:Immunoglobulin lambda-Chains; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009431:Neural Conduction / Q000502:physiology; D010265:Paraproteinemias / Q000150:complications*; D010951:Plasma Exchange; D011239:Prednisolone / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000209:etiology
D007146:Immunoglobulin lambda-Chains; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone